Hello, and thank you for standing by. My name is Mark, and I will be your conference operator today. At this time, I would like to welcome everyone to the Allurion Third Quarter Earnings Call.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q3 2025 Earnings Call Transcript November 12, 2025 Acumen Pharmaceuticals, Inc.

The third quarter of 2025 closed amid growing macroeconomic strain, policy unpredictability and renewed investor focus on execution risk. While ...

This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss ...

You’re reading The Checkup With Dr. Wen, a newsletter on how to navigate medical and public health challenges. Click here to ...

An oral small molecule drug may reduce gastrointestinal adverse events for adults using a GLP-1-based obesity drug, according ...

Glucagon-like peptide-1 receptor agonist was not associated with an increased rate of pancreatitis in patients with T2D or obesity.